Source link : https://www.newshealth.biz/health-news/drug-duo-enhances-myeloma-outcomes/
TOPLINE: Adding daratumumab to lenalidomide maintenance therapy after transplant in patients with multiple myeloma triples the minimal residual disease (MRD)–negative conversion rate to 50.5% vs 18.8% with lenalidomide alone. The combination therapy reduces progression risk by 47% and achieves estimated 30-month progression-free survival (PFS) rates of 82.7% vs 66.4% for lenalidomide alone. METHODOLOGY: A multicenter, […]
Author : News Health
Publish date : 2025-01-27 04:54:56
Copyright for syndicated content belongs to the linked Source.